# Itolizumab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/itolizumab

> Itolizumab, sponsored by Equillium, Inc. (EQ): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | itolizumab |
| Codes | EQ001, EQ101 |
| Sponsor | Equillium, Inc. (EQ) https://sec-api.dev/companies/eq/catalysts |
| Indications | acute graft-versus-host disease, or agvhd, where itolizumab, alopecia areata, or aa, and in june 2024, we, alopecia areata, or aa, in australia and new zealand, and in june 2024, we, moderate to severe alopecia areata, or aa, in australia and new zealand |
| Modality | antibody |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Nov 2022: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: moderate to severe alopecia areata, or AA, in Australia and New Zealand.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0000950170-24-126322): "In November 2022, we initiated a Phase 2 proof-of-concept clinical study of EQ101 administered intravenously, or IV, in subjects with moderate to severe alopecia areata, or AA, in Australia and New Zealand." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2024-11-13, last confirmed 2025-03-27.
- SEC Form 10-Q (accession 0000950170-24-126322): "In April 2024, we announced positive topline data from the Type B LN portion of that study." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm
- SEC Form 10-K (accession 0000950170-25-045726): "In April 2024, we announced positive topline data from the Type B LN portion of that study in which itolizumab (EQ001) was generally well-tolerated and demonstrated clinically meaningful responses in highly proteinuric patients where more than 80% of subjects achieved a greater than 50% reduction in urine protein creatinine ratio, or UPCR." https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm

### Jun 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: alopecia areata, or AA, and in June 2024, we.
- First seen 2024-11-13, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-045726): "We completed a Phase 2 proof-of-concept clinical study of EQ101 in subjects with alopecia areata, or AA, and in June 2024, we announced positive topline data from that study." https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-126322): "In June 2024 we announced positive topline results from our Phase 2 clinical study of EQ101 in subjects with AA, in which EQ101 was well-tolerated." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm
- SEC Form 10-K (accession 0000950170-25-045726): "We completed a Phase 2 proof-of-concept clinical study in subjects with alopecia areata, or AA, in Australia and New Zealand, and in June 2024, we announced positive topline data from that study." https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-126322): "In June 2024, we announced positive topline data from that study." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126288): "In addition, in collaboration with Equillium, our partner Biocon has recently completed a robust placebo-controlled Phase 2 study of itolizumab in biologic-na&iuml;ve patients with moderate to severe ulcerative colitis, and we expect topline data from this study also in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126288): "Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025" https://www.sec.gov/Archives/edgar/data/1746466/000095017024126288/eq-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-24-126322): "We expect topline data from that study in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1746466/000095017024126322/eq-20240930.htm

### Feb 2025: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-03-27, last confirmed 2025-03-27.
- SEC Form 10-K (accession 0000950170-25-045726): "In February 2025, we announced positive topline data from the study in which itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission" https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm
- SEC Form 10-K (accession 0000950170-25-045726): "In February 2025, we announced positive topline data from the study where itolizumab demonstrated a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo after 12 weeks of treatment." https://www.sec.gov/Archives/edgar/data/1746466/000095017025045726/eq-20241231.htm

### Mar 2025: topline data readout

- Status: completed, mixed. Date confidence: month. Stage: 3. Indication: acute graft-versus-host disease, or aGVHD, where itolizumab.
- First seen 2025-05-14, last confirmed 2025-08-14.
- SEC Form 10-Q (accession 0000950170-25-108834): "In March 2025, we announced topline results from our Phase 3 EQUATOR study of itolizumab (EQ001) in patients with acute graft-versus-host disease, or aGVHD, where itolizumab (EQ001) did not meet the Day 29 outcomes of complete response, or CR, a primary outcome, and overall response rate, or ORR, a key secondary outcome, but there was a clinically meaningful improvement in durable CR from Day 29 to 99, a key secondary outcome, and statistically significant evidence of clinical benefit was also observed on pre-specified secondary endpoints of duration of CR and failure free survival." https://www.sec.gov/Archives/edgar/data/1746466/000095017025108834/eq-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071389): "In March 2025, we announced topline results from our Phase 3 EQUATOR study of itolizumab (EQ001) in patients with acute graft-versus-host disease, or aGVHD, where itolizumab (EQ001) did not meet the Day 29 outcomes of complete response, or CR, a primary outcome, and overall response rate, or ORR, a key secondary outcome, but there was a clinically meaningful improvement in durable CR from Day 29 to 99, a key secondary outcome, and statistically significant evidence of clinical benefit was also observed on" https://www.sec.gov/Archives/edgar/data/1746466/000095017025071389/eq-20250331.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/itolizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Itolizumab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/itolizumab

```bibtex
@misc{secapidev_pdufa_itolizumab_20261116,
  title        = {Itolizumab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/itolizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_itolizumab_20261116","title":"Itolizumab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/itolizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
